Title :

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma

Author(s) :

Eroukhmanoff, Juliette [Auteur]

Castinetti, Frederic [Auteur]

Penel, Nicolas [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Salas, Sébastien [Auteur]

Journal title :

BMC Cancer

Abbreviated title :

BMC Cancer

Volume number :

16

Publication date :

2016-08-24

ISSN :

1471-2407

English keyword(s) :

Chordoma
Auto-immune thyroid dysfunction
Tyrosine kinase inhibitors
Mesh:Phenylurea Compounds/adverse effects*
Mesh:Graves Disease/chemically induced*
Mesh:Humans
Mesh:Imatinib Mesylate/adverse effects*
Mesh:Male
Mesh:Middle Aged
Mesh:Neoplasm Recurrence
Mesh:Local/drug therapy
Mesh:Niacinamide/adverse effects
Mesh:Chordoma/drug therapy*
Mesh:Antineoplastic Agents/adverse effects
Mesh:Protein Kinase Inhibitors/adverse effects*
Mesh:Niacinamide/analogs & derivatives*

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

While hypothyroidism has frequently been reported with the use of TKIs, the thyroid-stimulating hormone (TSH) suppressing effect of TKIs is rare, except for thyroiditis. We describe a case with progressive recurrent chordoma ...
Show more >While hypothyroidism has frequently been reported with the use of TKIs, the thyroid-stimulating hormone (TSH) suppressing effect of TKIs is rare, except for thyroiditis. We describe a case with progressive recurrent chordoma who initially became hyperthyroid in a context of autoimmunity under sorafenib treatment and later under imatinib treatment. A 57-year-old man with lumbar chordoma began daily treatment of 800 mg sorafenib. He did not have any other medication or recent iodinated-contrast exposure and his family history was negative for thyroid and autoimmune disease. There was no history of neck pain, irradiation or trauma, recent fever or viral illness. Pre-treatment TSH was normal. After 18 weeks of treatment, the patient presented hyperthyroidism with positive anti-TSH receptor antibodies. More surprisingly, Graves' disease recurred during treatment with imatinib. The fact that Graves' disease occurred after two different TKIs suggests that it could be a rare but important class effect. Anti-TSH receptor antibodies should be systematically measured when TSH decreases in order to avoid the erroneous diagnosis of transient hyperthyroidism due to thyroiditis.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T18:15:22Z
2020-04-07T17:04:31Z